Development of a Multidimensional Prediction Model for the Course and Outcome of Early-Onset Juvenile Idiopathic Arthritis (JIA)
Key facts
- Who runs it
- Istituto Giannina Gaslini
- Where
- Italy2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 130 people, planned
- Started
- 30 Jul 2024
- Expected to end
- 31 Dec 2028
- Type of study
- Observational, 2 groups
- Record updated
- 20 October 2026
Who can take part
- Age
- 2 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- For patients with JIA; A diagnosis of JIA according to the ILAR criteria by the treating pediatric rheumatologist; Classification in one of the following ILAR JIA categories: oJIA, RF-pJIA, PsA, or undifferentiated arthritis; Age < 6 years at onset; Onset of JIA symptoms no more than 6 months before enrolment; Duly executed, written, informed consent/assent obtained from the parents/patient; For control subjects
- A diagnosis of Iridocyclitis not correlated to JIA by the treating pediatric ophtalmologist
- Age ≤ 17 years at diagnosis
- Duly executed, written, informed consent/assent obtained from the parents/patient
Who cannot take part
- For patients with JIA; Classification in one of the following ILAR JIA categories: systemic arthritis, RF-positive polyarthritis, enthesitis-related arthritis; Previous treatment with any synthetic or biologic DMARD before biologic sample collection; For control subjects; ● Previous treatment with any synthetic or biologic DMARD before biologic sample collection
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 17 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a prospective-retrospective, translational, no profit, multicentric, observational study. A cohort of at least 100 early-onset JIA patients attending the Unit of Rheumatology and Autoinflammatory Diseases, Department of Pediatric Sciences, IRCCS Istituto Giannina Gaslini or selected Italian pediatric rheumatology centers, will be enrolled and evaluated at onset and at 5 time points of follow up to 24 months (month 3, month 6, month 12, month 18 and month 24) to monitor the course of the disease. A cohort of 30 patients with Iridocyclitis not correlated to JIA will be recruited in parallel at the time of disease diagnosis as a group of control for comparison.
The 2 groups in the trial
- Early-onset JIA patients
Early-onset Juvenile Idiopathic Arthritis (JIA) represents the most common form of arthritis in Western country, affecting the 70-80% of Italian children. It typically occurs before the age of 6, has female predilection, high frequency of positive antinuclear antibodies (ANA),and is characterized by a high risk (20-30% of cases) of chronic iridocyclitis
- Iridocyclitis patients not correlated to JIA
Group of control for comparison.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Fit questions
- Built from NCT07882667, who can take part
- Record updated
- 20 October 2026